DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients
Identification of cancer-specific methylation of DNA released by tumours can be used for non-invasive diagnostics and monitoring. We previously reported in silico identification of DNA methylation loci specifically hypermethylated in common human cancers that could be used as epigenetic biomarkers....
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-04-01
|
| Series: | Epigenetics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/15592294.2019.1695333 |
| _version_ | 1797678911571623936 |
|---|---|
| author | Lukas Vrba Marc M. Oshiro Samuel S. Kim Linda L. Garland Crystal Placencia Daruka Mahadevan Mark A. Nelson Bernard W. Futscher |
| author_facet | Lukas Vrba Marc M. Oshiro Samuel S. Kim Linda L. Garland Crystal Placencia Daruka Mahadevan Mark A. Nelson Bernard W. Futscher |
| author_sort | Lukas Vrba |
| collection | DOAJ |
| description | Identification of cancer-specific methylation of DNA released by tumours can be used for non-invasive diagnostics and monitoring. We previously reported in silico identification of DNA methylation loci specifically hypermethylated in common human cancers that could be used as epigenetic biomarkers. Using DNA methylation specific qPCR we now clinically tested a group of these cancer-specific loci on cell-free DNA (cfDNA) extracted from the plasma fraction of blood samples from healthy controls and non-small cell lung cancer (NSCLC) patients. These DNA methylation biomarkers distinguish lung cancer cases from controls with high sensitivity and specificity (AUC = 0.956), and furthermore, the signal from the markers correlates with tumour size and decreases after surgical resection of lung tumours. Presented observations suggest the clinical value of these DNA methylation biomarkers for NSCLC diagnostics and monitoring. Since we successfully validated the biomarkers using independent DNA methylation data from multiple additional common carcinoma cohorts (bladder, breast, colorectal, oesophageal, head and neck, pancreatic or prostate cancer) we predict that these DNA methylation biomarkers will detect additional carcinoma types from plasma samples as well. |
| first_indexed | 2024-03-11T23:06:49Z |
| format | Article |
| id | doaj.art-be6a36c8141c43ed944561d0b10cbecc |
| institution | Directory Open Access Journal |
| issn | 1559-2294 1559-2308 |
| language | English |
| last_indexed | 2024-03-11T23:06:49Z |
| publishDate | 2020-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Epigenetics |
| spelling | doaj.art-be6a36c8141c43ed944561d0b10cbecc2023-09-21T13:09:23ZengTaylor & Francis GroupEpigenetics1559-22941559-23082020-04-0115441943010.1080/15592294.2019.16953331695333DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patientsLukas Vrba0Marc M. Oshiro1Samuel S. Kim2Linda L. Garland3Crystal Placencia4Daruka Mahadevan5Mark A. Nelson6Bernard W. Futscher7The University of Arizona Cancer CenterThe University of Arizona Cancer CenterUniversity of ArizonaThe University of Arizona Cancer CenterThe University of Arizona Cancer CenterThe University of Arizona Cancer CenterThe University of Arizona Cancer CenterThe University of Arizona Cancer CenterIdentification of cancer-specific methylation of DNA released by tumours can be used for non-invasive diagnostics and monitoring. We previously reported in silico identification of DNA methylation loci specifically hypermethylated in common human cancers that could be used as epigenetic biomarkers. Using DNA methylation specific qPCR we now clinically tested a group of these cancer-specific loci on cell-free DNA (cfDNA) extracted from the plasma fraction of blood samples from healthy controls and non-small cell lung cancer (NSCLC) patients. These DNA methylation biomarkers distinguish lung cancer cases from controls with high sensitivity and specificity (AUC = 0.956), and furthermore, the signal from the markers correlates with tumour size and decreases after surgical resection of lung tumours. Presented observations suggest the clinical value of these DNA methylation biomarkers for NSCLC diagnostics and monitoring. Since we successfully validated the biomarkers using independent DNA methylation data from multiple additional common carcinoma cohorts (bladder, breast, colorectal, oesophageal, head and neck, pancreatic or prostate cancer) we predict that these DNA methylation biomarkers will detect additional carcinoma types from plasma samples as well.http://dx.doi.org/10.1080/15592294.2019.1695333cancer markerdna methylationbiomarkercfdnaliquid biopsynsclc |
| spellingShingle | Lukas Vrba Marc M. Oshiro Samuel S. Kim Linda L. Garland Crystal Placencia Daruka Mahadevan Mark A. Nelson Bernard W. Futscher DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients Epigenetics cancer marker dna methylation biomarker cfdna liquid biopsy nsclc |
| title | DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients |
| title_full | DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients |
| title_fullStr | DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients |
| title_full_unstemmed | DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients |
| title_short | DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients |
| title_sort | dna methylation biomarkers discovered in silico detect cancer in liquid biopsies from non small cell lung cancer patients |
| topic | cancer marker dna methylation biomarker cfdna liquid biopsy nsclc |
| url | http://dx.doi.org/10.1080/15592294.2019.1695333 |
| work_keys_str_mv | AT lukasvrba dnamethylationbiomarkersdiscoveredinsilicodetectcancerinliquidbiopsiesfromnonsmallcelllungcancerpatients AT marcmoshiro dnamethylationbiomarkersdiscoveredinsilicodetectcancerinliquidbiopsiesfromnonsmallcelllungcancerpatients AT samuelskim dnamethylationbiomarkersdiscoveredinsilicodetectcancerinliquidbiopsiesfromnonsmallcelllungcancerpatients AT lindalgarland dnamethylationbiomarkersdiscoveredinsilicodetectcancerinliquidbiopsiesfromnonsmallcelllungcancerpatients AT crystalplacencia dnamethylationbiomarkersdiscoveredinsilicodetectcancerinliquidbiopsiesfromnonsmallcelllungcancerpatients AT darukamahadevan dnamethylationbiomarkersdiscoveredinsilicodetectcancerinliquidbiopsiesfromnonsmallcelllungcancerpatients AT markanelson dnamethylationbiomarkersdiscoveredinsilicodetectcancerinliquidbiopsiesfromnonsmallcelllungcancerpatients AT bernardwfutscher dnamethylationbiomarkersdiscoveredinsilicodetectcancerinliquidbiopsiesfromnonsmallcelllungcancerpatients |